ALLK:NSD-Allakos Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 80.28

Change

0.00 (0.00)%

Market Cap

USD 3.93B

Volume

0.18M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Allakos Inc. operates as a clinical stage biopharmaceutical company. The company is developing antolimab (AK002) for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in Redwood City, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD69.85B 33.27 26.59
REGN Regeneron Pharmaceuticals, Inc

N/A

USD61.08B 21.61 16.69
SGEN Seattle Genetics, Inc

N/A

USD32.18B N/A N/A
MRNA Moderna, Inc

N/A

USD27.41B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

USD25.08B 29.87 27.00
BGNE BeiGene, Ltd

N/A

USD24.87B N/A N/A
RPRX Royalty Pharma plc

N/A

USD24.33B 34.81 9.50
GMAB Genmab A/S

N/A

USD23.71B 25.56 2.87
IMMU Immunomedics, Inc

N/A

USD19.73B N/A N/A
INCY Incyte Corporation

N/A

USD18.93B 47.64 35.20

ETFs Containing ALLK

Symbol Name Weight Mer Price(Change) Market Cap
SBIO ALPS Medical Breakthrough.. 0.00 % 0.50 %

N/A

USD0.19B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -15.81% 41% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.81% 41% F 42% F
Trailing 12 Months  
Capital Gain 1.53% 42% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.53% 41% F 55% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 36.06% N/A N/A 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 36.06% N/A N/A 87% B+
Risk Return Profile  
Volatility (Standard Deviation) 45.29% N/A N/A 26% F
Risk Adjusted Return 79.63% N/A N/A 87% B+
Market Capitalization 3.93B 91% A- 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 8.59 21% F 14% F
Price / Cash Flow Ratio -62.32 96% A 94% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -37.87% 75% C 28% F
Return on Invested Capital -26.90% 79% C+ 26% F
Return on Assets -23.42% 60% D- 17% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 37.26 1% F 0% N/A
Short Percent 35.45% 2% F 6% F
Beta 0.99 72% C- 59% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.